Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Windpessl, M; Gauckler, P; Zitt, E; Lhotta, K; Ay, C; Eller, K; Odler, B; Neumann, I; Rudnicki, M; Kronbichler, A; Säemann, MD.
[General recommendations for the management of glomerular diseases-2023].
Wien Klin Wochenschr. 2023; 135(Suppl 5): 696-704. Doi: 10.1007/s00508-023-02265-6 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Eller Kathrin
Odler Balazs
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Glomerular diseases are associated with extrarenal complications, such as thromboembolism, cardiovascular events and particularly infections. A thorough knowledge of the various immunosuppressants and their associated toxicity profile is therefore of great importance. While nephrologists usually have extensive experience with calcineurin inhibitors and antimetabolites, two other compounds (rituximab, in severe cases cyclophosphamide) are used comparatively infrequently and will be discussed in more detail. Moreover, practical recommendations for the prevention of thromboembolism in states of nephrosis and for the prophylaxis of Pneumcystic jirovecii pneumonia are provided.
Find related publications in this database (using NLM MeSH Indexing)
Humans - administration & dosage
Nephrotic Syndrome - administration & dosage
Cyclophosphamide - administration & dosage
Thromboembolism - administration & dosage

Find related publications in this database (Keywords)
Thromboembolism
Nephrotic syndrome
Rituximab
Cyclophophamide
Pneumocystis jirovecii
© Med Uni Graz • Impressum